PBA
ESPR icon

Paradigm Biocapital Advisors’s Esperion Therapeutics ESPR Stock Holding History

Paradigm Biocapital Advisors’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,719,831
Closed -$11.5M – 26
2022
Q3 		$11.5M Buy
1,719,831
+311,781
+22% +$2.14M 1.62% 20
2022
Q2 		$8.96M Buy
1,408,050
+250,804
+22% +$1.42M 1.79% 15
2022
Q1 		$5.37M Buy
1,157,246
+317,989
+38% +$1.36M 1.42% 22
2021
Q4 		$4.2M Buy
+839,257
New +$6.72M 1.2% 23

Other funds holding ESPR

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $4.85B AUM 144% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $50.9B AUM 42.89% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $57.5B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $134B AUM 35.51% 1-Year Est. Return